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Background: Streptococcus pneumoniae infections are a major cause of global morbidity and mortality, and the
emergence of antibiotic-resistant Streptococcus pneumoniae strains has been increasingly reported. This study
provides up-to-date information on bacterial serotype distribution and drug resistance from S. pneumoniae clinical
isolates that could guide prevention and treatment strategies for pneumococcal disease in China.
Methods: A total of 94 S. pneumoniae isolates were collected from outpatients and inpatients at one Chinese
hospital from 2011–2013. Drug susceptibility and resistance was determined by minimum inhibitory concentrations
(MICs). Capsular serotypes were identified by the quellung reaction test and multiplex polymerase chain reaction.
Results: Fifteen serotypes were identified among the 94 S. pneumoniae clinical isolates that were collected.
Prevalent serotypes were 19F (42.6 %), 19A (8.5 %), 3 (8.5 %), and 6B (7.4 %). Potential immunization coverage rates
for the 7-, 10- and 13-valent pneumococcal polysaccharide conjugate vaccines were 59.6, 62.6, and 79.6 %,
respectively. Resistance rates to tetracycline, erythromycin, and trimethoprim/sulfamethoxazole were 91.2, 80.2 and
63.8 %, respectively. Resistance rates to penicillin, amoxicillin, ceftriaxone, and cefotaxime were 47.3, 34.1, 19.8, and
18.7 %, respectively. In almost all cases, antimicrobial resistance of the S. pneumoniae isolates in patients five years
or younger was higher than isolates collected from patients aged 51 years or older.
Conclusion: Prevalent serotypes among the 94 S. pneumoniae clinical isolates were 19F, 19A, 3, and 6B. The
13-valent pneumococcal polysaccharide conjugate vaccine covered the majority of the serotypes identified in this
sample. Drug resistance varied among different serotypes and age groups. Clinical precautions should be taken to
avoid the development of multidrug resistance in this potential human pathogen.
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creasing incidence of antibiotic-resistant S. pneumoniae
strains worldwide poses a threat to the effective treatment
of these infections. The burden of pneumococcal diseases is
worsened by increasing numbers of people affected with
chronic disease (e.g. sickle-cell disease, chronic renal failure,
chronic liver disease, asplenia, and human immunodefi-
ciency virus) or mycobacterial infection, as well as an aging
population in many developed countries [2, 3]. Approxi-
mately 70–100 million children aged under 5 years die of S.
pneumoniae infection annually, and 90 % of these deathsle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
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that there were 12,815 cases/100,000/year of all-cause
pneumonia and 526 deaths/100,000 among children aged 1
to 59 months, and there were 14 cases/100,000/year of
meningitis between 1980 and 2008 [5]. Importantly, S.
pneumoniae is the most dominant causative agent of
community-acquired pneumonia among pediatric patients
[5–7].
The antigenicity of the S. pneumoniae capsular poly-
saccharide is diverse, and infection or vaccination with
S. pneumoniae can stimulate the production of a specific
protective antibody that exhibits cross protection against
certain serotypes. A number of multivalent vaccines have
been developed to reduce the disease burden caused by
specific pneumococcal serotypes. The recently developed
polysaccharide conjugate vaccine (PPV) PPV23 vaccine
contains purified capsular polysaccharides from 23 sero-
types (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14,
15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F) that
collectively account for 85–90 % of invasive pneumococ-
cal disease (IPD) cases among adults; however, it is not
recommended for infants. The S. pneumoniae polysac-
charide capsule largely determines virulence and this
structure remains the target of many current pneumococ-
cal vaccines. Notably, there are at least 94 S. pneumoniae
serotypes that differ in their nasopharyngeal carriage
prevalence, invasiveness, and disease incidence. Some of
these serotypes exhibit a distinctive epidemiology that
includes their potential to cause invasive disease, their
incidence in specific age groups and geographic regions,
and their resistance to different antibiotics [1].
Antibiotic-resistant pneumococci have been steadily in-
creasing since the 1990s and are becoming a major prob-
lem worldwide. The emergence of multidrug-resistant S.
pneumoniae (MDRSP) has been observed in various coun-
tries over the past several decades. The growing resistance
of S. pneumoniae to commonly used antibiotics empha-
sizes the urgent need for effective vaccines that control
pneumococcal disease. A subset of capsular polysaccha-
rides cloned from clinically important serotypes is in-
cluded in PCV. The introduction of PCVs into national
immunization programs can substantially decrease the in-
cidence of IPD caused by vaccine-type pneumococci in
many countries [8–10]. More specifically, PPV PCV7,
PCV10 and PCV13 have proven effective in decreasing
the infection rate of S. pneumoniae and preventing the
emergence of MDRSP [11, 12].
The aim of this study was to determine the sero-
type distribution and antimicrobial susceptibility of S.
pneumoniae isolates among pediatric and older pa-
tients, as well as the immunization coverage rates for
PCV7 (covering serotypes 4, 6B, 9V, 14, 18C, 19F and
23F), PCV10 (PCV7 plus serotypes 1, 5 and 7F) and
PCV13 (PCV10 plus serotypes 3, 6A and 19A).Methods
Clinical isolates and culture conditions
This study was conducted at the Sun Yat-Sen Memorial
Hospital, a teaching hospital located in Guangzhou,
China. A total of 94 pneumococcal isolates collected at
the hospital from January 2011 to June 2013 were in-
cluded in this study. The study was approved by the Eth-
ics Committee of Sun Yat-Sen Memorial Hospital and
each patient or parent guardian from which the isolates
were collected provided informed consent prior to study
commencement.
Invasive S. pneumoniae isolates were recovered from
clinical specimens of normally sterile body sites such as
blood (10.6 %), cerebral spinal fluid (CSF) (6.4 %), and
pleural fluid (7.4 %). Non-invasive S. pneumoniae isolates
were recovered from clinical specimens such as sputum,
tracheal/bronchial aspirates (lower respiratory tract speci-
mens) (60.6 %), and ear secretions (14.9 %). To avoid sam-
ple duplication, isolates that were consecutively isolated
from the same individual were excluded. For each patient,
data on demographics and clinical, radiological, and other
outcomes relevant to the study were recorded and ana-
lyzed. Patients’ ages ranged between 1 month and 92 years,
with an average of 40 ± 24 years. The male to female ratio
was 2.07: 1 (no. of males = 64, 68 %; no. of females = 30,
32 %).
Gram-positive samples were grown on 5 % sheep
blood agar and incubated at 37 °C in the presence of 5 %
CO2 for 18–24 h prior to biochemical and molecular as-
says. All isolates were stored at −80 °C in a fat-free milk
preservation medium until analyses were performed.
Identification of isolates
S. pneumoniae isolates were identified by colony morph-
ology, the alpha hemolysis test, the optochin sensitivity test
(Oxoid, Basingstoke, UK), bile solubility, the catalase test,
and the Omni antiserum assay (Statens Serum Institute,
Copenhagen, Denmark). Conventional microbiological
methods were used in combination with the VITEK® 2 mi-
crobial analysis system according to the manufacturer’s in-
structions (bioMérieux, La Balme-les-Grottes, France).
Susceptibility testing
The antimicrobial susceptibility of each isolate was tested
using the VITEK® 2 S. pneumoniae susceptibility card
(AST-GP68, bioMérieux) according to the 2013 guidelines
created by the Clinical and Laboratory Standards Institute
(CLSI). >The minimum inhibitory concentration (MIC) of
each isolate was determined against the following 15 anti-
microbial agents: penicillin, amoxicillin, cefotaxime, ceftri-
axone, ertapenem, meropenem, erythromycin, levofloxacin,
moxifloxacin, ofloxacin, linezolid, vancomycin, tetracycline,
chloramphenicol, and trimethoprim/sulfamethoxazole.
For penicillin, meningitis criteria were set as follows:
Fig. 1 Serotype distribution among clinical specimens and age
groups. a. Proportion and serotype distribution of S. pneumoniae
isolates collected from different specimen sources. b. Proportion and
serotype distribution of S. pneumoniae isolates among the different
age groups
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mL. Non-meningitis criteria for penicillin were as follows:
susceptible, MIC ≤ 2 μg/mL; resistant, MIC ≥ 8 μg/mL.
For cefotaxime and ceftriaxone, meningitis criteria were
as follows: susceptible, MIC ≤ 0.5 μg/mL; resistant, MIC ≥
2 μg/mL. Non-meningitis criteria for cefotaxime and cef-
triaxone were set as follows: susceptible, MIC ≤ 1 μg/mL;
resistant, MIC ≥ 4 μg/ml. Isolate ATCC 49619 and
Staphylococcus aureus ATCC 29213 were used as quality
control strains during susceptibility testing. MDRSP iso-
lates were defined as isolates that were resistant to three
or more classes of antimicrobial agents.
Serotyping
All isolates were serotyped by a capsular quellung reac-
tion test using type-specific antisera (Statens Serum
Institute, Copenhagen, Denmark) against serotypes
present in the 23-valent PPV (i.e. 1, 2, 3, 4, 5, 6B, 7F, 8,
9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20,
22F, 23F, and 33F). Serotyping was performed by phase-
contrast microscopy as described previously [13]. Strains
that could not be serotyped by a quellung reaction test
were serotyped using multiplex PCR [14].
Molecular capsular typing
Genomic DNA was extracted from the bacterial cultures
using the DNeasy Blood & Tissue Kit (Qiagen Multiplex
PCR Kit, Hilden, Germany). Primer sequences were pub-
lished by the Center for Disease Control and Prevention
(CDC) (http://www.cdc.gov/streplab/pcr.html). A total
of 28 primers were grouped into nine multiplex re-
actions. Primers used in this study are listed in
Additional file 1: Table S1 and PCR reactions conditions
were performed as described previously [15], with minor
modifications. Briefly, multiplex PCR was performed in
50 μl volumes and each reaction mixture contained the
following reagents: 5 μl 10 × PCR buffer (Qiagen Multi-
plex PCR Kit), 5 μl DNA sample, 1 μl dNTPs (50 μM/
μl), 1 μl Taq (5 U/μl), 37 μl H2O; 0.5 μl Primer F; and
0.5 μl Primer R. PCR tubes were placed in a thermocy-
cler (DNA Engine, BioRad, Hercules, California, USA)
programmed for initial denaturation at 94 °C × 4 min,
followed by 30 amplification cycles at 94 °C × 45 s, an-
nealing at 54 °C × 45 s, extension at 72 °C × 2 min, and a
final extension at 72 °C × 10 min. PCR products were
electrophoresed in a 2 % agarose gel at 50–100 volts for
40 min, stained with ethidium bromide, and visualized
by transillumination (Ultra-Violet Products Ltd., Upland,
California, USA).
Statistical analysis
All data were analyzed with WHONET software (version
5.6, WHO Collaborating Centre). Statistical comparisons
were made using the Chi-squared and Fisher’s exact testscalculated by SPSS software (version 19.0). Two-tailed
P values < 0.05 were considered statistically significant.
Results and discussion
Demographics
A total of 94 S. pneumoniae isolates were prospectively
collected from patients with pneumococcal infections at
one Chinese hospital from 2011 to 2013. Of these, the
most prevalent specimen sources were sputum and tra-
cheal/bronchial aspirates (lower respiratory tract speci-
mens) (n = 57, 60.6 %), followed by ear secretions
(n = 14, 14.9 %), blood (n = 10, 10.6 %), CSF (n = 6,
6.4 %), and pleural fluid (n = 7, 7.4 %) (Fig. 1a,
Additional file 1: Table S2). The rate of pneumococcal
infections was higher in male patients (68 %) than in fe-
male patients (32 %), but this difference was not statisti-
cally significant (P = 0.61). Chaïbou et al. reported
similar infection rates among males in Burkina Faso
(257/476, 55 %) and findings by Bos et al. were similar
among males in Mozambique (150/177, 85 %) [16, 17].
In contrast to patient sex, the serotype distribution dis-
played some age-dependent variation (Fig. 1b, Additional
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different between all three defined age groups (≤5 years,
6 ~ 50 years, and ≥ 51 years), but these differences may
have been related to the limited number of serotypes
present. Among the 94 isolates, 42 (44.7 %) were isolated
from children (≤5 years) and 44 (46.8 %) were isolated
from patients ≥ 51 years.
Serotype distribution and immunization coverage
Of the 94 S. pneumoniae isolates analyzed, 54 were iden-
tifiable by capsular serotyping. Of the remaining 40
isolates, 26 were identified using multiplex PCR, and 14
isolates (14.9 %) could not be serotyped. The serotype
distribution of these S. pneumoniae isolates is shown in
Fig. 2a and Additional file 1: Table S4. The most com-
monly isolated serotypes were 19F (n = 40, 42.6 %), 19A
(n = 8, 8.5 %), 3 (n = 8, 8.5 %), 6B (n = 7, 7.4 %), and 23F
(n = 4, 4.3 %). These five serotypes accounted for 71.3 %
of the isolates. Serotypes 19F and 19A were the two
dominant types. Interestingly, we did not find any
recently discovered serotype 6C and 6D strains that were
reportedly isolated from [18, 19].
Serotype distributions varied according to age (Fig. 1b,
2b, c and Additional file 1: Table S3). Serotype distribu-
tion was similar in patients ≤ 5 years and patients older
than 51 years. However, the rank order of these sero-
types varied. Among the patients who were younger
than 5 years, the most common serotypes were 19F
(50 % of isolates), 6B (9.5 %), 19A (7.1 %), 3 (4.8 %),
and 15 (4.8 %); these accounted for 73.8 % of the iso-
lates in this age group. In contrast, the most common
serotypes in patients 51 years or older were 19F
(38.6 %), 3 (11.4 %), 19A (9.1 %), 6B (6.8 %), and 23F
(2.3 %); these accounted for 68.2 % of the isolates in
this age group. Serotypes 16F, 17, and 33 were only de-
tected in patients aged between 6 and 50 years (Fig. 1b,
Additional file 1: Table S3).
PPVs comprise a combination of pneumococcal poly-
saccharide with an immunogenic protein carrier that
can enhance the host’s antibody response and induce
immunological memory. PCV7 covered serotypes 4 6B,
9V, 14, 18C, 19F, and 23F. PCV10 covered all serotypes
covered by PCV7, as well as serotypes 1, 5, and 7F.
PCV13 covered all serotypes covered by PCV10, as well
as serotypes 3, 6A, and 19A. Overall immunization
coverage rates for PCV13, PCV10, and PCV7 were
79.6, 62.6, and 59.6 %, respectively. Importantly, we
determined that PCV immunization coverage is higher
in children younger than 5 years, despite numerous
reports that this age group is at the highest risk of de-
veloping IPD [7]. However, there was no significant dif-
ference in the proportions of PCV7-specific serotypes,
PCV10-specific serotypes, or PCV13-specific serotypes
of patients younger than 5 years (71.4, 71.4, and 83.3 %,respectively) and those patients 51 years or older (54.9,
59.1, and 79.5 %, respectively). Furthermore, the pro-
portion of PCV10-specific serotypes was lower in
patients younger than 5 years than in patients 51 years
or older (0 versus 4.4 %, P = 0.23). Last, the proportion of
PCV13-specific serotypes was similarly lower in patients
younger than 5 years (11.9 % versus 20.0 %, P = 0.03)
(Fig. 2b, c and Additional file 1: Table S5).Antimicrobial susceptibility
Antimicrobial susceptibilities determined for the clinical
isolates analyzed in this study are shown in Fig. 3a and
Additional file 1: Table S6. The percentage of these
isolates that conferred resistance to tetracycline, erythro-
mycin, and trimethoprim/sulfamethoxazole was 91.2, 80.2,
and 63.8 %, respectively; the percentage of isolates that
conferred resistance to penicillin and amoxicillin was 47.3
and 34.1 %, respectively; and the percentage of isolates
that conferred resistance to ceftriaxone and cefotaxime
was 19.8 and 18.7 %, respectively. All isolates were suscep-
tible to ertapenem, quinolone, linezolid and vancomycin,
with the exception of one isolate (1.1 %) that was inter-
mediately susceptible to ofloxacin, and 4 (4.4 %) isolates
that were intermediately susceptible to ertapenem.
Almost all antimicrobial resistance rates for isolates
collected from the pediatric patient group (≤5 years)
were higher than those collected from patients 51 years
or older (Table 1). More specifically, the percentage of S.
pneumoniae isolates that was resistant to amoxicillin
and erythromycin was significantly higher in the
pediatric group than in patients aged 51 years or older
(P < 0.05) (Fig. 3b). Because 19F was the dominant sero-
type, we also compared the antimicrobial susceptibility
of 19 F to that of the other types. Serotype 19F had a
higher rate of resistance to penicillin, amoxicillin, ceftri-
axone, cefotaxime, erythromycin, and trimethoprim/
sulfamethoxazole than all other serotypes (Fig. 3c and
Additional file 1: Table S6; P < 0.05).
According to the revised CLSI breakpoints for paren-
teral penicillin (i.e. MIC ≥ 8 μg/mL for resistant non-
meningitis isolates and MIC ≥ 0.12 μg/mL for resistant
meningitis isolates), the proportion of invasive and non-
invasive isolates that conferred penicillin resistance was
56.5 and 28.2 %, respectively. The proportion of invasive
and non-invasive isolates that conferred resistance to
cefotaxime was 26.1 and 12.7 %, respectively, and the
proportion of invasive and non-invasive isolates that
conferred resistance to ceftriaxone was 26.1 and 14.1 %,
respectively. In summary, these results indicate that the
resistance rates of these S. pneumoniae isolates to mul-
tiple antibiotics, with the exception of meropenem and
amoxicillin, were much higher in invasive infections
than in non-invasive infections.
Fig. 2 Serotype distribution and PCV immunization coverage among the S. pneumoniae isolates. a. Serotypes and immunization coverage rates of
PCVs among all age groups. b. Serotypes and immunization coverage rates of PCVs among children≤ 5 years. c. Serotypes and immunization
coverage rates of PCVs among patients≤ 51 years
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Fig. 3 Antibiotic susceptibility of S. pneumoniae isolates. a. Antibiotic susceptibility. b. Comparison of antibiotic resistance between patients≤ 5 years
and patients≤ 51 years. c. Comparison of antibiotic resistance between serotype 19F and other serotypes. d. Comparison of antibiotic resistance
between invasive and non-invasive S. pneumoniae isolates. * P < 0.05
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was found in 73.4 % (n = 69) of these isolates (61.7 and
6.4 % in the non-meningitis and meningitis isolates,
respectively). The most common MDR pattern observed
was resistance to erythromycin, tetracycline, and trimetho-
prim/sulfamethoxazole (n = 58, 61.7 %), followed by resist-
ance to penicillin antibiotics, erythromycin, and tetracycline
(n = 49, 52.1 %). Notably, antibiotic resistance was limited
to a number of specific pneumococcal serotypes. A high
MDR rate was primarily found in serotypes 19F (n = 37/94,
39.4 %) and 19A (n = 7/94, 7.4 %) serotypes. However, PCV
immunization coverage included the majority of the sero-
types that conferred MDR phenotypes (PCV7, 71.0 %;
PCV10, 72.5 %; and PCV13, 89.9 %). In addition, most
penicillin-nonsusceptible isolates were covered by PCVs
(Table 2).
S. pneumoniae normally inhabits the nasopharynx,
throat, and oral cavity. However, pneumococcal infec-
tions remain a major medical problem as they are a
major cause of morbidity and mortality in children
and adults, and emerging resistance to conventionalantibiotics further complicates this issue. Tracking
serotype distribution and antibiotic resistance patterns
may prove useful in the development and effective use of
PCVs.
To date, S. pneumoniae serotype distribution report-
edly varies by age, geography, disease, and time [1, 20].
One study of 2173 S. pneumoniae isolates collected
worldwide between 2004 and 2009 showed that the most
common serotypes found in Latin America were sero-
types 1, 6A, and 14. In South Africa/Mauritius, the most
common serotypes were 19F, 6B, 4 and 23F, while, sero-
type 19A was the most common among North American
isolate and it was more prevalent among children than
adults [1]. In Europe, the most commonly isolated S.
pneumoniae serotypes were 3,,14, 1 and 7F [1]. In Shen-
zhen, China, the most common serotypes of invasive S.
pneumoniae isolates were found children 14 years or
younger; these included serotypes 19F, 14, 23F, 19A and
6B [7, 21]. In this study, we determined that the most
common serotype in clinical isolates sampled at a hospital
in Guangzhou, China is 19F, and this is in agreement with
Table 1 Susceptibility of 15 antimicrobials for S. pneumoniae isolates from different groups














Amoxicillin 50.0 31.2 0.04 57.5 15.7 0.04 13.0 32.4 0.04
Penicillin G 68.0 50.0 0.28 70.0 29.4 0.04 56.5 28.2 0.03
Cefotaxime 28.0 18.8 0.12 32.5 7.8 0.05 26.1 12.7 0.04
Ceftriaxone 32.0 18.8 0.11 35.0 7.8 0.02 26.1 14.1 0.04
Chloramphenicol 4.0 15.6 0.04 5.0 13.7 0.16 13.0 1.4 0.01
Erythromycin 96.0 75.0 0.04 95.0 68.6 0.03 87.0 78.9 0.35
Tetracycline 92.0 87.5 0.41 97.5 86.3 0.39 100 90.1 0.23
Trimethoprim/sulfamethoxazole 47.6 45.5 0.22 82.5 50.0 0.02 65.2 63.4 0.29
Meropenem 24.0 21.9 0.27 17.5 13.7 0.51 8.7 14.1 0.03
Ertapenem 0 0 - 0 0 - 0 0 -
Levofloxacin 0 0 - 0 0 - 0 0 -
Moxifloxacin 0 0 - 0 0 - 0 0 -
Ofloxacin 0 0 - 0 0 - 0 0 -
Linezolid 0 0 - 0 0 - 0 0 -
Vancomycin 0 0 - 0 0 - 0 0 -
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and other Southeast Asian countries [19–21]. Other com-
mon serotypes that we identified in our study (19A, 6B,
and 23F, are in agreement with previous reports as well
[21–23]. However, in contrast to prior studies [21–24], we
found that serotypes 3 and 15 were also common sero-
types in our sample. These data suggest that serotype dis-
tribution differs regionally.
Age is a risk factor for pneumococcal infections
[5, 16, 20, 25]. The age profile of the patients infected
with S. pneumoniae in this study exhibits a typical
twin-peak distribution. Most patients in our cohortTable 2 Antimicrobial resistance of S. pneumoniae isolates
The serotypes
of isolates
% of resistant isolates




47.3 80.2 91.2 63.8
Serotype
19F (n = 40) 27.9 40.4 41.5 35.1
19A (n= 8) 4.3 8.5 8.5 7.4
6B (n = 7) 3.2 6.4 6.4 2.1
3 (n = 8) 2.1 2.1 7.4 2.1
Otherserotypesa
(n = 18) 4.9 13.2 14.6 10.7
Untyped
(n = 14)
4.9 9.6 12.8 6.4
aIncluded are 11 serotypes
bMultidrug-resistant isolates, i.e. resistant to three or four tested antimicrobials
cThe PCVs covered the majority of serotypes that had MDR (n = 69) phenotypes [PCwere infected with serotypes 19F, 6B, or 19A, and
serotype distribution among pediatric patients and pa-
tients 51 years or older were consistent with the
overall serotype distribution.
As S. pneumoniae spreads in a community, serotype
distribution among one age group can directly and indir-
ectly affect serotype distribution in other age groups de-
pending on community mixing patterns [26]. In one
study, a decrease in PCV7 serotypes among children
younger than 5 years was observed over a 1-year period,
and a similar decrease in PCV7 serotypes was also ob-
served in adults 65 years or older [27]. PCV7 was therim/
xazole
Cephalosporin Chloramphenicol Meropenem MDRb,c
19.8 9.9 15.4 73.4
14.1 3.4 9.7 39.4
0 0 0 7.4
0 0 0 4.3
1.1 0 0 2.1
3.5 5.3 3.4 12.8
1.1 1.2 2.3 7.4
V7, 71.0 % (49/69); PCV10, 72.5 % (50/69); and PCV13, 89.9 % (62/69)]
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has been put to use in more than 70 countries [11, 28].
In many industrialized countries, the widespread use of
this vaccine has led to a dramatic decline in PCV7-
serotype IPDs not only in vaccinated children, but also
in the general unvaccinated population [29–31]. This
may have partially contributed to a shift toward non-
PCV7 serotype IPDs, and the observed increase in sero-
type 19A. It is also worth noting that the antimicrobial
resistance of S. pneumoniae serotype 19A is evolving with
the widespread use of antibiotics [32–34].
PCV immunization coverage varies among different
populations and geographic regions [35]. Reports suggest
that after switching from PCV7 to PCV10, the proportion
of serotypes covered has increased to varying degrees in
the USA, Europe, Africa and Asia, and switching from
PCV10 to PCV13 further improved global immunization
coverage by 4–7 % [12, 36]. Among children with pneu-
monia in five Chinese hospitals, replacing PCV7 with
PCV10 increased immunization coverage rates by ap-
proximately 0.6 %, whereas replacing PCV10 with PCV13
increased coverage by approximately 15.4 % [37]. We
found that the overall immunization coverage rates of
PCV7, PCV10, and PCV13 were 59.6, 62.6 and 79.6 %, re-
spectively, and these findings are similar to those reported
by Ma [7]. However, the immunization coverage rates for
these vaccines were higher in pediatric patients than in
patients 51 years or older, although this difference was not
significant. Immunization coverage for serotypes 3, 15,
and 19A by PCV13 may be responsible for the significant
increase in coverage observed when switching from PCV7
and PCV10 to PCV13. We suggest that PCV13 be intro-
duced into the vaccination program in Guangzhou, China
as it may protect a greater proportion of the Chinese
population from developing pneumococcal disease.
Over the past two decades, the incidence of pneumococ-
cal infections caused by antimicrobial-resistant pneumo-
cocci has increased [38]. To date, the epidemiology of S.
pneumoniae and potential risk factors for the development
of MDR have not been assessed in China. This knowledge
is essential for selecting the most appropriate empirical
antimicrobial therapy for these infections. Recently, the
Asian Network for Surveillance of Resistant Pathogens
(ANSORP) study group performed a prospective surveil-
lance study on serious pneumococcal infections in Asian
countries. Antibiotic resistance to β-lactams and macrolides
was commonly observed. Furthermore, high prevalence
rates (≥60 %) of penicillin-nonsusceptible S. pneumoniae
(PNSP) were reported for Taiwan, Korea, Japan, and
Vietnam, while Europe and the US had prevalence rates of
approximately 30.0 % [38]. In China, increasing cross-
resistance to penicillin and erythromycin has been ob-
served, with a higher pneumococcal resistance rate to
erythromycin than in the western countries [5, 39]. Inaddition, the reported infection rate of PNSP among
children in Guangzhou, China was 78.0 % from 2001 to
2002, and 83.6 % in 2008 [15]. Of 171 invasive S. pneumo-
niae isolates sampled from 11 hospitals in 11 cities from
2006–2008, 96.0 and 75.0 % of isolates conferred resist-
ance to erythromycin and trimethoprim/sulfamethoxazole,
respectively, while 77.0 and 30.0 % of meningeal isolates
conferred resistance to penicillin and ceftriaxone, respec-
tively [21]. In this study, we determined that the PNSP
prevalence rate was 70.4 %, while resistance rates to
erythromycin and tetracycline were 80.2 and 91.2 %,
respectively. These data demonstrate that penicillin,
erythromycin, and tetracycline are not appropriate for
treating S. pneumoniae infections in the Guangzhou re-
gion. Conversely, we found that resistance rates to ceftri-
axone (19.8 %), cefotaxime (18.7 %), meropenem (15.4 %)
are lower than those reported in other Chinese studies
[7, 40]. This may be caused by different treatment strat-
egies, specimen sources, or diseases studied in the
Guangzhou area compared with other regions in China.
Levofloxacin is a broad-spectrum fluoroquinolone with
greater antimicrobial activity against S. pneumoniae than
older fluoroquinolones. However, increased use of fluoro-
quinolones has allowed for increasing emergence of
levofloxacin-resistant pneumococci [41, 42]. Kang et al.
[43] recently reported that approximately 4.7 % of
pneumococcal isolates collected from individuals affected
with community-acquired pneumonia in Asian countries
were levofloxacin-nonsusceptible, and that independent
risk factors for levofloxacin-nonsusceptible pneumococcal
pneumonia were prior treatment with fluoroquinolones,
cerebrovascular disease, and healthcare-associated infec-
tions. The dissemination of non-antimicrobial-susceptible
clones has been a major factor in the emergence of
antibiotic-resistant S. pneumoniae and pneumococcal re-
sistance to fluoroquinolones is primarily caused by muta-
tions in the quinolone resistance-determining regions of
the parC and gyrA genes [44]. In the present study, we did
not find any strains that were resistant to fluoroquino-
lones, but approximately 1.1 % of the isolates were
ofloxacin-nonsusceptible. Although the prevalence of
fluoroquinolone resistance at present remains low in this
region, ongoing surveillance is necessary.
None of the isolates investigated in this work were
resistant to ertapenem, linezolid or vancomycin. These
data suggest that these drugs could replace penicillin as
the first line of treatment for S. pneumoniae infections.
However, it is important to note that serotype 19F is the
most common type in China [5], and our results are in
agreement that 19F had a higher rate of resistance to peni-
cillin, ceftriaxone, cefotaxime, amoxicillin, and erythro-
mycin. Moreover, 73.4 % of the S. pneumoniae isolates
collected were MDRSP, and these results echo those of a
previous study in Asian countries [38].
Huang et al. BMC Infectious Diseases  (2015) 15:312 Page 9 of 10Together, these data confirm that antibiotic resistance
is a serious problem in China. The inappropriate use of
antibiotics may partially explain the high resistance rate
observed, and MDR serotypes likely play an important
role in this phenomenon. Fortunately, PCV7 and PCV13
cover 71.0–89.9 % of the MDR pneumococcal isolates
collected. Thus, they both have potential for controlling
MDRSP. Given that serotype 19A plays an important
role in the development of S. pneumoniae-related infec-
tions in China, however, PCV13 may be more useful
than PCV7.Conclusion
A higher incidence of S. pneumoniae infections exists
among children five years or younger and in adults
51 years or older. Given the high prevalence and clinical
impact of pneumococcal antibiotic resistance, continuous
surveillance of pneumococcal epidemiology is strongly
warranted. This study also provides important data on S.
pneumoniae serotype distribution and immunization
coverage that could influence vaccination strategies in
Guangzhou, China. Importantly, drug resistance trends
vary with different S. pneumoniae serotypes and patient
age groups. Clinical precautions should be taken to avoid
the emergence of MDR in S. pneumoniae. Results ob-
tained from this study may provide clinical guidance for
the use of antimicrobial agents and the scientific basis for
the independent development of vaccine policy in
Guangzhou, China.Additional file
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